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Abstract
Background—Cigarette smoking is a major risk factor for COPD and COPD severity. Previous
genome-wide association studies (GWAS) have identified numerous single nucleotide
polymorphisms (SNPs) associated with the number of cigarettes smoked per day (CPD) and a
Dopamine Beta-Hydroxylase (DBH) locus associated with smoking cessation in multiple
populations.
Objective—To identify SNPs associated with lifetime average and current CPD, age at smoking
initiation, and smoking cessation in COPD subjects.
Methods—GWAS were conducted in 4 independent cohorts encompassing 3,441 ever-smoking
COPD subjects (GOLD stage II or higher). Untyped SNPs were imputed using HapMap (phase II)
panel. Results from all cohorts were meta-analyzed.
Results—Several SNPs near the HLA region on chromosome 6p21 and in an intergenic region
on chromosome 2q21 showed associations with age at smoking initiation, both with the lowest
p=2×10−7. No SNPs were associated with lifetime average CPD, current CPD or smoking
cessation with p<10−6. Nominally significant associations with candidate SNPs within alpha-
nicotinic acetylcholine receptors 3/5 (CHRNA3/CHRNA5; e.g. p=0.00011 for SNP rs1051730) and
Cytochrome P450 2A6 (CYP2A6; e.g. p=2.78×10−5 for a nonsynonymous SNP rs1801272)
regions were observed for lifetime average CPD, however only CYP2A6 showed evidence of
significant association with current CPD. A candidate SNP (rs3025343) in the DBH was
significantly (p=0.015) associated with smoking cessation.
Conclusion—We identified two candidate regions associated with age at smoking initiation in
COPD subjects. Associations of CHRNA3/CHRNA5 and CYP2A6 loci with CPD and DBH with
smoking cessation are also likely of importance in the smoking behaviors of COPD patients.
Keywords
Chronic Obstructive Pulmonary Disease (COPD); Genome Wide Association study (GWAS);
smoking behaviors; Single Nucleotide Polymorphism (SNP)
INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is a common, genetically complex disease
caused, and accelerated in its progression, predominantly by tobacco smoking. High
smoking intensity, likely related at least in part to nicotine addiction, increases the risk of
developing COPD. Although many patients quit smoking after they are diagnosed with
COPD, some continue to smoke, placing them at high risk for continued disease
progression.
Smoking behaviors, such as age at smoking initiation, smoking cessation, and number of
cigarettes smoked per day (CPD), are partially genetically determined and have substantial
heritability.1–4 Numerous loci and candidate genes have been suggested to contain genetic
markers affecting smoking behaviors using genome-wide linkage scans 5 and genome wide
association study approaches.67 Recent Genome Wide Association Studies (GWAS) have
identified loci associated with smoking cessation (Dopamine Beta-Hydroxylase on
chromosome 9q34) and CPD (e.g. nicotinic acetylcholine receptor locus on chromosome
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15q25 and Cytochrome P2A6 (CYP2A6) locus on chromosome 19q13) in multiple
populations,8–11 although GWAS of smoking behaviors specifically within COPD subjects
have not been reported. Interestingly, the same single nucleotide polymorphisms (SNPs) in
the 15q25 locus were previously associated with development of COPD,12 but the role of
this locus in smoking behaviors in COPD patients and whether the sole effect of this locus
on COPD susceptibility relates to smoking behavior remain unclear.
Due to their typically heavy lifetime smoking exposures, potentially related to (at least in
part) enrichment in genetic variants responsible for nicotine addiction, COPD subjects can
be considered as a unique population for studying smoking behaviors. However, diagnosis
and further progression of COPD are likely to modify smoking status (i.e. increased efforts
to quit smoking) and smoking intensity (e.g. reduction of CPD). Identifying genetic factors
involved in smoking cessation is of special importance in clinical practice, since quitting
smoking may reduce subsequent loss of lung function in COPD patients.1314 Smoking
cessation results in an improvement of respiratory symptoms in COPD patients, and is
associated with reduced mortality due to COPD.13–16 Another smoking-related phenotype,
age at smoking onset, correlates with nicotine dependence in adulthood 17 and mortality due
to COPD.15 Taken together, it is of special interest to search for markers associated with
smoking behaviors uniquely among COPD patients. Likewise, it is of importance to assess
whether SNPs, regarded as established genetic determinants of smoking cessation and CPD
in other populations, associate with these traits in COPD patients as well. Identification and
description of such genetic variations may have significant consequences on future, targeted
therapy aiming to reduce smoking among COPD patients.
The aim of the current study was to identify SNPs associated with age at smoking initiation,
smoking cessation, current and lifetime average CPD among COPD subjects, using GWAS
in four independent cohorts: National Emphysema Treatment Trial (NETT), Evaluation of
COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE), GenKOLS
cohort from Bergen, Norway, and COPDGene. We hypothesized that a subset of smoking
behavior genetic determinants in other population samples would influence smoking
behavior in COPD subjects.
METHODS
Subjects and phenotypes
Ever-smoking, Caucasian subjects with at least moderate COPD (GOLD stage II or higher)
from four independent cohorts (NETT,18 ECLIPSE,19 GenKOLS cohort from Bergen,
Norway,20 and COPDGene (first 1000 subjects)21) were studied (Table 1). In total 3,441
subjects had at least 1 (out of 4) non-missing, smoking-related phenotype (Table 1). All
phenotypes were self-reported using either Case Report Form (smoking status and the
lifetime average CPD in the ECLIPSE cohort) or modified versions of the American
Thoracic Society/Division of Lung Diseases Respiratory Disease Questionnaire.22 Since
current smokers were not eligible for the NETT study, this cohort did not contribute to the
analyses on smoking cessation and current CPD.
Genotyping and quality control (QC)
Different genotyping chips from Illumina (Illumina Inc., San Diego, CA) were used (table
1). QC steps were previously described in detail for the NETT, Norwegian and ECLIPSE
cohorts,23 and were applied to the COPDGene study as well. Briefly, QC steps consisted of
filtering SNPs based on missing call rates (>5%) and Hardy-Weinberg Equilibrium
deviation (p<10−8), and filtering subjects based on genotyping call rate (<95%), sex
discrepancy, unexpected relatedness (PLINK pi-hat cutoff of 0.125), and ethnicity. Removal
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of cases that were outliers for genetic ancestry was performed based on principal
components (PCs) analysis in cases only. In the primary analysis, untyped markers were
imputed using 120 founder Caucasian (Centre d’Etude du Polymorphisme Humain (Utah
residents with ancestry from northern and western Europe) (CEU)) haplotypes from
HapMap reference panel (phase II) and, as a secondary analysis, using 1000 Genomes
Project data.2425 We limited our analysis to SNPs genotyped/imputed in at least 2 cohorts,
with imputation r2 coefficient ≥0.3 (for imputed SNPs only). Overall, approximately 2.5 and
6.3 million SNPs per phenotype were analyzed using the reference HapMap Project and
1000 Genomes Project panels, respectively.
Association analysis of candidate SNPs
We extracted candidate SNPs achieving genome-wide significance in the previous studies
on smoking cessation and CPD.8–1126 Following previous GWAS,89 we additionally
extracted two SNPs from CYP2A6 (rs1801272 (Leu160His)) and CHRNA5 (rs588765) based
on their biological function. Since a candidate SNP from the DBH locus and most of the
candidate SNPs from the CYP2A6 locus were imputed in all cohorts, we searched for the
best proxy SNP genotyped in at least 3 of the cohorts.
Statistics
According to Box-Cox transformation 27 that identified approximately the best
transformation of dependent variables, which could be applied to all cohorts, we studied
log2-transformed age at smoking initiation and lifetime average CPD, and the square root of
the current CPD. Regression models were run under an additive model coded SNPs, while
adjusting for potential confounders (see online supplementary material for details). A fixed
effect model was used for all meta-analyses. Effect allele was defined as the one associated
with later age at smoking initiation, higher CPD or higher odds for smoking cessation. Meta-
analytic p<5×10−8 was considered as genome-wide significant;28 5×10−8 ≤p<5×10−7 was
interpreted as a suggestive association in the genome-wide panel with p<0.05 a suggestive
association for candidate SNPs.
Software
Box-Cox transformations were performed with MASS package 27, while lambda inflation
factors were calculated with GenABEL package 29 in R (ver. 2.10.1).30 SNP imputation was
performed with MACH (ver. 1.0).31 PCs, reflecting genetic structure of each study
population, were calculated and analyzed with the EIGENSOFT package (ver. 2.0).32
Genetic association analyses and meta-analyses were run with PLINK (ver. 1.0.7).3334
SNAP (ver. 2.2) 35 was used to search for proxy SNPs (r2≥0.8) using the Caucasian
HapMap phase II panel and to assess linkage disequilibrium (LD) coefficients in 1000
Genomes Project data. SNP/gene annotations and regional association plots were created
with LocusZoom (ver. 1.1; human genome build hg18).36
RESULTS
Age at smoking initiation
Analyses in the individual cohorts were adjusted for sex and principal components for
genetic ancestry. In total, meta-analysis included 3,397 subjects for the age at smoking
initiation phenotype. Lambda inflation factors were between 0.986 and 1.019 for individual
cohorts (table 1), and 1.002 for meta-analytic p values (see online supplementary figure 1
for a Q-Q plot of meta-analysis). No SNPs showed meta-analytic association p values below
the genome-wide significance level. Numerous SNPs in the intergenic region on
chromosome 2q21 and in the region between BCL2-antagonist/killer 1 (BAK1) and Zinc
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finger and BTB domain containing 9 (ZBTB9) on chromosome 6p21 were associated with
age at smoking initiation at a suggestive significance level (figure 1 and online
supplementary table 1). In total 24 SNPs were associated with age at smoking initiation with
p<10−5 in the meta-analysis (online supplementary table 1).
Lifetime average CPD
Analyses in single cohorts were adjusted for sex, age and principal components for genetic
ancestry. In total, meta-analysis included 3,440 subjects for the lifetime average CPD
phenotype. Lambda inflation factors were between 0.996 and 1.018 for individual cohorts
(table 1), and 1.019 for meta-analytic p values (see online supplementary figure 2 for a Q-Q
plot of meta-analysis). Thirteen SNPs were associated with lifetime average CPD with meta-
analytic p<10−5, however, no SNPs showed association with meta-analytic p<10−6 (table 2).
Candidate SNPs from the nicotinic acetylcholine receptor locus on chromosome 15q25
(rs578776, rs588765, rs8034191, rs1051730 and rs16969968) were significantly (p<0.05)
associated with lifetime average CPD with the same direction of effect as seen in previous
GWAS on CPD (table 2). The synonymous rs1051730 SNP was the top associated SNP in
this locus (figure 2).
Four candidate SNPs (rs7251570, rs4105144, rs1801272 and rs12461383) in the CYP2A6
locus on chromosome 19q13 were significantly (p<0.05) associated with lifetime average
CPD with the same direction of effect as seen in previous GWAS on CPD (table 2). A non-
synonymous SNP (rs1801272) was the second most significantly associated SNP in this
locus (figure 2, table 2). There is, at most, a moderate level of LD between these 4 SNPs
according to the HapMap phase II panel (r2≤0.6 and D’≥0.84, see online supplementary
figure 3). Analysis of proxy SNPs that were genotyped in at least three cohorts was
performed. Analysis of rs8102683 (genotyped in the NETT, ECLIPSE and Norwegian
cohorts, and imputed in COPDGene) that is a proxy for rs4105144 (r2=0.87), and rs7251418
(genotyped in all cohorts) that is a proxy for rs7251570 (r2=0.81) confirmed the associations
observed (p= 4.65×10−5 (B=0.074 for the “C” effect allele; I2=0) and p=0.0024 (B=0.054
for the “G” effect allele; I2=0), respectively). No genotyped proxy SNPs could be found for
rs12461383 and rs1801272 SNPs. We did not replicate, with a nominal p<0.05, associations
between SNPs in 7p14, 8p11 and 10q23 loci, reported in previous GWAS on CPD in our
analysis on lifetime average CPD (online supplementary table 2).
Smoking cessation
Analyses in single cohorts were adjusted for age, % of predicted FEV1 and principal
components summarizing genetic ancestry. In total, meta-analysis included 1,164 current
smokers (defined as “No” for smoking cessation) and 1,907 former smokers (defined as
“Yes” for smoking cessation). Lambda inflation factors were between 0.995 and 1.000 for
individual cohorts (table 1), and 0.998 for meta-analytic p values (see online supplementary
figure 4 for a Q-Q plot of meta-analysis). No SNPs showed association with meta-analytic
p<10−6 (table 3). Candidate SNP rs3025343 in the DBH locus showed nominally significant
association with smoking cessation with the same direction of effect as seen in recent
GWAS, yet with substantial heterogeneity between studies (table 3). SNP rs3025316, a
proxy for rs3025343 (r2=0.94), was genotyped in all cohorts and confirmed this association
(p= 0.002 (OR= 1.32 for the “T” effect allele; I2=18).
Current CPD
Analyses were adjusted for sex, age, % of predicted FEV1, and principal components for
genetic ancestry. In total, meta-analysis included 1,113 current smokers for the current CPD
phenotype. Lambda inflation factors were between 0.995 and 1.005 for individual cohorts
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(table 1), and 1.010 for meta-analytic p values (see online supplementary figure 5 for a Q-Q
plot of meta-analysis). No SNPs showed meta-analytic association with p<10−6 (table 4).
Among candidate SNPs, rs12461383 from the CYP2A6 locus was significantly associated
with current CPD with the same effect direction as compared to previous GWAS on CPD
(table 4). Candidate SNPs rs1801272 and rs7251570 showed borderline significant
association with the same effect direction as compared to previous GWAS on CPD (table 4).
We did not replicate, at a nominal p< 0.05, associations between SNPs in 7p14, 8p11 and
10q23 loci reported in previous GWAS on CPD in our analysis on current CPD (online
supplementary table 3).
Analyses of SNPs Imputed with 1000 Genomes Project Data
Analysis of all phenotypes using SNP genotypes imputed using the 1000 Genomes Project
revealed 20 additional associations below the suggestive genome-wide significance level
(supplementary table 4). SNP rs9394152 in the 6p21 locus was the most significantly
associated SNP with the age at smoking initiation (meta-analytic p=6.55×10−8) and,
similarly to the majority of SNPs associated with this phenotype below suggestive genome-
wide significance level, was characterized by high (≥0.96), cohort-specific imputation r2
coefficients (supplementary table 4). We observed novel associations of 3 SNPs with the
lifetime average CPD; the most significantly associated SNP rs28675338 (r2=0.07 and
D’=1.00 to rs1051730 according to 1000 Genomes Project Data) maps to the 15q25 locus.
We also found one SNP associated with smoking cessation, with meta-analytic p<5×10−7
(supplementary table 4). Since cohort-specific, imputation r2 coefficients of the 4 SNPs,
associated with lifetime average CPD and smoking cessation below suggestive genome-
wide significance level, were rather modest (range 0.35–0.64; supplementary table 4), the
observed associations certainly require additional confirmation and should be interpreted
with caution. The three SNPs associated with current CPD with meta-analytic p<5×10−7
map to regions on chromosomes 2 and 3 (supplementary table 4), which were already
ranked as top loci using the HapMap II reference panel (table 4).
DISCUSSION
Cigarette smoking is the most important environmental risk factor for COPD, and smoking
cessation is the most important therapeutic intervention to prevent its progression. Our
current study identified two loci on chromosomes 2q21 and 6p21 as candidates for
containing genes influencing age at smoking initiation in COPD patients, both showing
suggestive levels of genome-wide significance. Furthermore, this study confirmed that
certain SNPs in the nicotinic acetylcholine receptor locus on chromosome 15q25 and SNPs
in the CYP2A6 locus on chromosome 19q13 were associated with CPD in COPD patients.
Of importance, we additionally confirmed in COPD subjects the previously reported
association of a marker (rs3025343) in the DBH locus with smoking cessation.
The two loci mapping to chromosomes 2q21and 6p21showed evidence of association with
age at smoking initiation at a suggestive genome-wide significance level, using both
HapMap II and 1000 Genomes projects reference imputation panels. The association peaks
found here do not localize within any known genes, suggesting distant regulation of yet
unidentified target genes may be involved. SNPs from chromosome 6p21 are located close
to the Human Leukocyte Antigen locus, and ZBTB9 and BAK1 are the closest genes to the
association peak. The BAK1 gene, encoding a proapoptotic protein, has been previously
associated by GWAS with testicular germ cell tumors 37 and platelet number.38 Yet SNPs
identified in these studies do not correlate, in terms of LD, with top SNPs from our age at
smoking initiation GWAS.
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Analysis of candidate SNPs, with respect to the lifetime average CPD, revealed that the
majority of those SNPs in the CHRNA3/CHRNA5 (15q25) and CYP2A6 (19q13) regions
significantly associated with this trait showed the same direction of effect described
previously.8–1126 However, SNPs from the 7p14, 8p11 (CHRNB3/CHRNA6 locus) and
10q23, as well as some SNPs from the CYP2A6 and CHRNA3/CHRNA5 loci, were not
replicated in the current study with a nominal significance threshold. This may be caused by
effect sizes that are too small to be detected in our populations or potentially to different
genetic determinants of smoking behaviors within COPD subjects.
Besides the “neutral” or reference haplotype, it has been suggested there are at least 2 other
haplotypes with independent effects on CPD in this 15q25 region.2639 Our study confirms
previous observations that rs1051730, and tagging SNPs such as rs16969968, exhibit
relatively strong effects in this region, and SNPs rs588765 and rs578776, determine
independent haplotypes associated with lifetime CPD in COPD patients as well. However,
we could not replicate association between lifetime average CPD and rs684513, i.e. the top
SNP in the analysis on CPD when conditioning for rs1051730 in the Tobacco and Genetics
Consortium.10 Importantly, the effect directions of all candidate SNPs in this 15q25 locus
agree with those previously reported, suggesting larger COPD cohorts are required to
establish significance of independent SNPs/haplotypes in this region.
Interestingly, effect sizes of replicated SNPs from the CHRNA3/CHRNA5 locus are similar
to most of those from the CYP2A6 locus in our study, which contrasts with recent GWAS
where bigger effect sizes were seen for the former locus.8 Additionally, variations in the
CHRNA3/CHRNA5, but not CYP2A6, locus showed substantial heterogeneity in genetic
effects in our study, and as observed in previous GWAS as well.810 We speculate that this
might be due to between-study differences in general (e.g. educational status or peer
smoking40) or COPD-specific (e.g. reporting lifetime average CPD which may be
influenced by severity of disease) characteristics.
Analysis of current CPD, which was much less powered than lifetime CPD due to a lower
number of subjects, was still able to detect some evidence of association with markers near
CYP2A6, yet not for those located in the CHRNA3/CHRNA5 region. CYP2A6 is an enzyme
primarily responsible for conversion of nicotine to cotinine in the liver, and rs1801272
(Leu160His) codes for the CYP2A6*2 allele, which inactivates the enzyme.41 This SNP
showed the largest effect size on both current and lifetime average CPD among all analyzed
candidate SNPs in the region. Leu160His is in LD (D’=1.0) with other SNPs that were
replicated in the CYP2A6 locus. This agrees with previous GWAS and suggests that the
rs1801272 SNP may be a true causative variant, while the other associations observed may
be due to partial tagging by this SNP.8 Importantly, we show that the genotyped proxy SNPs
in the CYP2A6 locus confirmed our analysis on imputed SNPs with respect to lifetime
average CPD. The lack of convincing association for the proxy SNP rs7251418 with current
CPD may be explained by the relatively smaller sample size in this analysis, and incomplete
LD between the target and the proxy SNPs. Previous GWAS suggested that other genes may
be associated with CPD in the 19q13 region, yet we observed no nominally significant
associations for EGLN2, RAB4B and CY2B6.
Analysis of smoking cessation did not reveal any loci associated below the suggestive
significance level, and it showed that the previously reported 10 association between
rs3025343 in the DBH locus can be replicated in COPD subjects with a nominal significance
threshold. DBH is a plausible candidate gene for smoking cessation since it participates in
the metabolism of dopamine. This neurotransmitter is released from neurons in response to
nicotine,3 and is an important mediator of addiction behaviors such as smoking. The
rs3025343 SNP that we extracted showed a substantial heterogeneity in this effect, which
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may reflect the between-study differences in factors such as use of nicotine replacement
therapy or socio-economic status. Interestingly, the best proxy SNP rs3025316 (genotyped
in all cohorts) showed a more pronounced effect with somewhat smaller heterogeneity index
compared to the rs3025343.
Our study possesses several limitations, and some of those are typical for many GWAS. For
example, the size of the current study may have been too small to detect associations at a
genome wide significance level. Phenotypes studied are genetically complex and are likely
determined by many genes of modest effects, which makes them difficult to detect with
genome-wide significance for the currently studied sample size. It is worth noting that the
much larger Tobacco and Genetics Consortium did not identify any genome-wide significant
associations for age at smoking initiation in a meta-analysis encompassing over 20,000
individuals.10 This emphasizes the need for even larger studies to study smoking behaviors
in order to detect variants with presumably low effect sizes. Despite the modest effect sizes
of the genetic variants implicated by GWAS, key biological pathways may be identified
using such approaches. Secondly, the genotype imputation accuracy could have had an
impact on our results. Many top SNPs from the analyses of age at smoking initiation were
imputed in all 4 cohorts; however, the association peaks of these regions also contained
SNPs genotyped in the majority (or even all) of the cohorts, which likely makes these
findings more reliable. Given the fact that different, and not fully overlapping, genotyping
chips were used, this imputation was crucial to obtain a comprehensive overview of many
genetic associations. In our study, this is of special importance for the nonsynonymous SNP
rs1801272 in CYP2A6, which had to be imputed in all cohorts and has no known proxy
SNPs. Assuming that the association of this SNP with CPD is a true positive and possibly
causal, imputation was the only one way to detect it. Lastly, we must acknowledge that
COPD diagnosis has a significant impact on smoking behaviors studied, and especially on
current CPD and smoking cessation. We took into account the severity of COPD, reflected
in the level of lung function, as a potential confounder when analyzing these two
phenotypes. However, we hypothesize that additional factors such as frequency of
exacerbations may also affect smoking behaviors in the COPD subjects that were studied
here. Additionally, it is plausible that social factors, such as smoking trends changing over
time, are important environmental determinants of smoking initiation and intensity, and they
might have potentially confounded genetic associations found.
In summary we identified two candidate loci associated with age at smoking initiation in
COPD patients. We show that variation in the CHRNA3/CHRNA5 locus on chromosome
15q25 locus and the CYP2A6 locus on chromosome 19q13 were associated with lifetime
average CPD among COPD patients. The latter gene may play a significant role in the
current smoking intensity among COPD patients. Future studies in larger populations of
COPD subjects will be required to determine the overlap between genetic determinants of
smoking behavior in the general population and in COPD subjects.
Supplementary Material
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Figure 1. Regional association plots of two loci including SNPs associated with age at smoking
initiation with meta-analytic p<10−6
Dots correspond to meta-analyzed SNPs. Color of dots corresponds to r2 (linkage
disequilibrium (LD) coefficient in the HapMap II CEU population; grey dots correspond to
SNPs with missing LD information) relative to the most significantly associated SNP
(depicted with diamond) in the region i.e. rs13408379 (top figure) and rs9380362 (bottom
figure).
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Figure 2. Regional association plots of the candidate loci centered on CHRNA3 (top) and
CYP2A6 (bottom) and their associations with lifetime average number of cigarettes smoked per
day
Dots correspond to meta-analyzed SNPs. Color of dots correspond to r2 (linkage
disequilibrium (LD) coefficient in the HapMap II CEU population; grey dots correspond to
SNPs with missing LD information) relative to the most significantly associated SNP in the
region (depicted with diamond) i.e. rs1051730 in the CHRNA3 (top figure) and rs1496402
(bottom figure; the second top SNP in this region is a nonsynonymous (Leu160His)
rs1801272 SNP in the CYP2A6).
CHRNA3=alpha-nicotinic acetylcholine receptor 3; CYP2A6=Cytochrome P450 2A6
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